NVS—Slide #48 graphs 10-year price vs QALYs for eight approved rare-disease drugs. A trend line has been fitted to these eight data points, and AXVS-101 intersects the trend line at a (10-year) price of $4M, based on a 13.3 QALY estimate by NVS.
I would caution against over-analyzing this chart.
News 
Market Data 
Discover 
